Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1614 1624 1626
This examiner grants 52% of resolved cases
Joshua Alexander Atkinson works in Tech Center 1600 and Art Unit 1612. He has completed 82 resolved cases, providing a moderate sample size for analysis. The allowance rate of 52.4 percent reflects a balanced outcome, where applications have a similar chance of being granted or abandoned. The median time to allowance is 1270 days, which indicates a moderate to long prosecution cycle. This 1270-day timeline is an essential factor for applicants to consider when filing in this art unit.
An interview lift of 26.7 percent suggests that speaking directly with the examiner provides a meaningful advantage. This 26.7 percent lift can help move applications toward the 52.4 percent allowance threshold more effectively. For the 82 resolved cases, the data indicates that interviews are a productive use of resources. Practitioners should account for the 1270-day median when managing their prosecution strategy. The lift suggests that verbal advocacy can be a decisive factor in achieving a positive outcome under this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | Non-Final OA | Nant Holdings IP, LLC |
| 18679874 | METHOD OF IMPROVING ANTIDANDRUFF EFFICACY BY USE OF A BOOSTER COMPOSITION IN COMBINATION WITH A HAIR CARE COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18723232 | OIL-IN-WATER TYPE D-PHASE EMULSION COMPOSITION WITH EXCELLENT EMULSION STABILITY | Final Rejection | LG H&H CO., LTD. |
| 18364891 | Click chemistry hydrogel with minimal swelling as a dural sealant and local delivery vehicle for recombinant proteins and other bioactive agents | Non-Final OA | Johns Hopkins University |
| 18280522 | NEW MICROPARTICLES CONTAINING ACTIVE SUBSTANCES | Non-Final OA | BASF SE |
| 18275042 | LIQUID HERBICIDAL COMPOSITIONS | Non-Final OA | BASF SE |
| 17999603 | NEW TRINEXAPAC-ETHYL MICROEMULSION COMPOSITIONS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18697559 | IONIC LIQUIDS FOR DRUG DELIVERY | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18157953 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING CARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR | Final Rejection | SK BIOPHARMACEUTICALS CO., LTD. |
| 18262088 | POWDEROUS COMPOSITION (III) | Non-Final OA | DSM IP Assets B.V. |
| 18041479 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17613220 | PREBIOTIC COMPOSITIONS | Final Rejection | Evonik Operations GmbH |
| 18909697 | Magneto-Patterned-Cell-Laden Hydrogel Materials and Methods of Making and Using Same | Non-Final OA | United States Government as represented by the Department of Veterans Affairs |
| 18719686 | COMPOSITION FOR LIGHTENING KERATIN FIBRES AND PROCESS FOR LIGHTENING KERATIN FIBRES USING THIS COMPOSITION | Non-Final OA | L'OREAL |
| 18716212 | SILICONE-FREE INVERSE EMULSION COMPRISING A C3 OR C4 ALKANEDIOL, GLYCEROL, A NONVOLATILE VEGETABLE OIL, A POLYGLYCERYL POLYRICINOLEATE SURFACTANT AND A VOLATILE ALKANE | Final Rejection | L'OREAL |
| 17800830 | COMPOSITION FOR FORMING ARTIFICIAL SKIN, AND USAGE METHOD THEREFOR | Non-Final OA | Shiseido Company, Ltd. |
| 18266143 | MOF NANOPARTICLES | Final Rejection | Cambridge Enterprise Limited |
| 18477383 | METHODS AND COMPOSITIONS FOR THE ABLATION OF NERVES | Final Rejection | TULAVI THERAPEUTICS, INC. |
| 17945038 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Non-Final OA | Nulixir Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy